esophageal squamous cell carcinomas
Showing 1 - 5 of 5
Esophageal Squamous Cell Carcinomas, Concurrent Chemoradiotherapy, Immunotherapy Trial (chemo combined with PD-1 inhibitors)
Not yet recruiting
- Esophageal Squamous Cell Carcinomas
- +3 more
- chemotherapy combined with PD-1 inhibitors
- (no location specified)
Nov 17, 2022
Esophageal Squamous Cell Carcinomas Trial in Beijing (SI-B001, Irinotecan)
Recruiting
- Esophageal Squamous Cell Carcinomas
-
Beijing, Beijing, ChinaBeijing Cancer Hostital
Mar 14, 2022
Esophageal Squamous Cell Carcinomas Trial (PF regimen (cis-platinum ; 5-fluorouracil ) combined with PD-1
Not yet recruiting
- Esophageal Squamous Cell Carcinomas
- PF regimen (cis-platinum ; 5-fluorouracil ) combined with PD-1 inhibitors（pembrolizumab）
- (no location specified)
Nov 1, 2021
Esophageal Squamous Cell Carcinomas Trial in Fuzhou (Camrelizumab, radiotherapy)
Recruiting
- Esophageal Squamous Cell Carcinomas
- Camrelizumab
- radiotherapy
-
Fuzhou, Fujian, ChinaFuzhou General Hospital
Feb 3, 2021
Esophageal Squamous Cell Carcinomas Trial in China (Nimotuzumab, Paclitaxel, Cisplatin)
Unknown status
- Esophageal Squamous Cell Carcinomas
- Nimotuzumab
- +3 more
-
Hefei, Anhui, China
- +26 more
Jan 29, 2016